# A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

> **NCT05286619** · PHASE2 · RECRUITING · sponsor: **University of Malaya** · enrollment: 63 (estimated)

## Conditions studied

- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05286619
- **Lead sponsor:** University of Malaya
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-22
- **Primary completion:** 2025-12
- **Final completion:** 2028-12
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286619, "A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05286619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*